Mental Health

Grow Therapy Unveils AI-Powered Between-Session Reflections to Deepen Therapy Insights

The new tool uses artificial intelligence to help clients and therapists surface focus areas before each session, making therapy sessions…

4 months ago

60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

90-day trial measuring change in general fatigue in chronic babesiosis patientsEnrollment expected to commence Q4 2025 and to be completed…

4 months ago

Walking Alone at Night is the Greatest Safety Fear of Women Nationwide — Almost Half Say Safety Concerns Limit Daily Activities LogicMark Poll Reveals

More women turn to technology solutions, with 71% looking to discreet devices for safetyLOUISVILLE, Ky., Aug. 19, 2025 (GLOBE NEWSWIRE)…

4 months ago

Silo Pharma’s PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) Pathway

SPC-15’s intranasal spray formulation meets safety standards for clinical trial development SARASOTA, FL, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Silo…

4 months ago

Aptitude Development Expands Partnership with Counslr to Offer 24/7 Mental Health Support Across All Properties Nationwide

Unlimited, 24/7 text-based mental health support available to student residents as demand for wellness amenities grows Student Housing Wellness Amenities…

4 months ago

Custom Health Acquires PatchRx to Expand Patient Connected Care Platform

Integration of PatchRx's adherence technology and connected dispensing strengthens Custom Health's vertically integrated, data-driven medication management for patients, providers, and…

4 months ago

MedWellAi, Inc Joins Trump Mobile In Engaging BrighterMD To Develop Ai-Inhanced Healthcare Telemedicine Platform, Focused On $24.46 Billion Corporate Wellness Market

CLEARWATER, Fla., Aug. 18, 2025 /PRNewswire/ -- MedWell Ai, Inc, ("Company") (OTCQB: MWAI) is pleased to confirm the collaboration and execution…

4 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and Provides Corporate Update

NRx Drug Development Grant of expanded Fast Track Designation for NRX-100 from the FDA for all indications and types of…

4 months ago

Reunion Neuroscience Announces Positive Topline Results from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD)

-- Achieved Primary Endpoint with 30mg Dose of RE104 Demonstrating 23.0-Point Reduction from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS)…

4 months ago